Companies › CrystalGenomics
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Camrelizumab (SHR-1210) Programmed cell death protein 1 antagonist | PDCD1 | Phase 2 | Non Squamous Non Small Cell Lung Cancer | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05841472 | Camrelizumab (SHR-1210) | Phase 2 | Non Squamous Non Small Cell Lung Cancer | Oncology | Dec 2026 |
Taizhou Hanzhong biomedical Agenus Partner Therapeutics STCube Ambrx
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.